FDA Approves Sanofi, Regeneron Treatment for Chronic Rhinosinusitis with Nasal Polyposis

By Michael Dabaie

Sanofi (SNY) and Regeneron Pharmaceuticals Inc. (REGN) said the U.S. Food and Drug Administration approved Dupixent, or dupilumab, for use with other medicines to treat chronic rhinosinusitis with nasal polyposis in adults whose disease isn't controlled.

Sanofi and Regeneron are jointly developing dupilumab under a global collaboration agreement. CRSwNP is a chronic disease of the upper airway that obstructs the sinuses and nasal passages.

Dupilumab is the first biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis, the companies said. Dupixent significantly reduces nasal polyp size and improves congestion and loss of smell, while reducing the need for surgery and systemic corticosteroids, the companies said.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

June 26, 2019 14:15 ET (18:15 GMT)

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024